Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsis

Fundraise brings lead product, TriVerity™ Test, closer to commercialization following recent submission to FDA SUNNYVALE, Calif., Sept. 12, 2024 /PRNewswire/ — Inflammatix, a pioneering molecular diagnostics company, announced today the closing of $57 million in Series E financing, led…